Biommune Pharma Technologies Llp Profile
Key Indicators
- Obligation of Contribution ₹ 1.00 Cr
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
About Biommune Pharma Technologies Llp
Biommune Pharma Technologies Llp (BPTL) is 8 Year, 11 Months old Limited Liability Partnership 04 February 2016. Its registered office is in Kolkata, West Bengal, India.
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 1.00 Cr as per MCA.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN/FCRN
AAF-6355
- Incorporation Date
04 Feb 2016
- Date of Accounts and Solvency Statement
31 Mar 2023
- ROC Code
Roc-Kolkata
- Company Classification
Limited Liability Partnership
Industry
Who are the key members and board of directors at Biommune Pharma Technologies Llp?
Designated Partners (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shib Nagsarkar  | Designated Partner | 04-Feb-2016 | Current |
| Gopi Dey | Designated Partner | 04-Feb-2016 | Current |
| Bithin Biswas | Designated Partner | 04-Feb-2016 | Current |
| Arijit Sarkar | Designated Partner | 04-Feb-2016 | Current |
| Joydeb Bhattacharjee | Designated Partner | 04-Feb-2016 | Current |
| Buddhadeb Biswas | Designated Partner | 04-Feb-2016 | Current |
Financial Performance of Biommune Pharma Technologies Llp.
Enhance accessibility to Biommune Pharma Technologies Llp's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Biommune Pharma Technologies Llp?
Unlock access to Biommune Pharma Technologies Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Upsurge Management Consultants LlpShib Nagsarkar is a mutual person
- Upasham Hospital Private Limited
Shib Nagsarkar is a mutual person
- Aragya Health Care Private Limited
Arijit Sarkar is a mutual person
Charges (Loans)
There are no Open Charges registered against the LLP as per our records.
How Many Employees Work at Biommune Pharma Technologies Llp?
Biommune Pharma Technologies Llp has a workforce of 6 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biommune Pharma Technologies Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biommune Pharma Technologies Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.